Hims & Hers Health shares rose after the FDA announced plans to review peptides for potential inclusion on the 503A bulk list, which would allow these drugs to be compounded individually by prescription. This regulatory move could create new revenue opportunities for Hims as it expands its peptide business, a sector the company has been developing since acquiring a peptide facility in 2025. While peptides are gaining attention as a growth area beyond GLP-1 drugs, clinical evidence for many peptide therapies remains limited and regulatory approval is still in early stages, with an advisory meeting scheduled for July 2026. Investors see peptides as a promising but long-term growth avenue for the telehealth company.
